Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARETTA: Neoadjuvant Paclitaxel in Nigerian Women with Breast Cancer
NCT03058939Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection in breast cancer, sponsored by University of Chicago. Primary endpoints: Overall Clinical Response Rate at 24 months and Pathologic Complete Response at 24 months. Planned start Nov 2018; status: withdrawn.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03058939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058939.